tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |
| Dinçkan A et al. | Evaluation of the first 100 liver transplantations. | 2008 | Turk J Gastroenterol | pmid:18386237 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Roth D et al. | A prospective study of hepatitis C virus infection in renal allograft recipients. | 1996 | Transplantation | pmid:8623154 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Zoppo A et al. | Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. | 1999 | Transplantation | pmid:10551656 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Timmermann W et al. | Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. | 1999 | Transplantation | pmid:10401762 |
| Kaufman DB et al. | Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. | 1999 | Transplantation | pmid:10071032 |
| Bozorgzadeh A et al. | Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. | 2004 | Transplantation | pmid:15087773 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Diem HV et al. | Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. | 2003 | Transplantation | pmid:12777858 |
| Smets F et al. | Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. | 2002 | Transplantation | pmid:12042647 |
| Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Andoh TF et al. | Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. | 1994 | Transplantation | pmid:7509514 |
| Imado T et al. | Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. | 2004 | Transplantation | pmid:14966413 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
| Pacifico L et al. | Tacrolimus and food allergy. | 2003 | Transplantation | pmid:14688538 |
| Vyas S et al. | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. | 1999 | Transplantation | pmid:10030303 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Boots JM et al. | Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. | 2002 | Transplantation | pmid:12499885 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
| Molmenti EP et al. | Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. | 2001 | Transplantation | pmid:11213072 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
| Vincenti F et al. | One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8669100 |
| Bolley R et al. | Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. | 2002 | Transplantation | pmid:11923712 |
| Burger CI et al. | Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. | 2010 | Transplantation | pmid:20440199 |
| Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |